Meir Hospital

IMPROVATE held two-day medical innovation and networking conference in Budapest, sparking groundbreaking deals between European representatives and leading Israeli medical technology companies

Retrieved on: 
Wednesday, April 27, 2022
Clalit Health Services, Robotics, HLS, Hospital, List of Medknow Publications academic journals, Weizmann Institute of Science, Patient, Technology, Acute kidney injury, Category:Medwell Journals academic journals, Health, Knowledge, COVID-19, MHealth, Person-centered therapy, Sterilization, Medicine, Synergy, Cardiology, Meir Hospital, Solution, PSIS, Partnership, CEO, Sheba Medical Center, State, Sleep apnea, Tel HaShomer, Dr. G: Medical Examiner, Tissue, TEL, Surgeon, Food, Hadassah Medical Center, HMO, Transformation, Emergency Medical Treatment and Active Labor Act, Martinsburg Mining, Manufacturing & Improvement Co. Historic District, VC, ALTA, Pharmacy, Innovation, 3D, Alta, Critical care, Coat of arms of the Romanian Ministry of Internal Affairs, Risk, Mobile phone, 3D printing, Pharmaceutical industry

TEL AVIV, Israel, April 27, 2022 /PRNewswire/ -- IMPROVATE, a platform for connecting change-makers and decision-makers, held a two-day medical innovation conference and business meet-up in Budapest, Hungary, with the participation of speakers and representatives from countries across Central and Eastern Europe, including several former presidents and prime ministers.

Key Points: 
  • Following the event, several business deals have already been initiated between European representatives and Israeli medical technology companies:
    GMedical , which develops health monitoring systems, is in talks with a European network of hospitals that also participated in the conference.
  • In addition, several other contacts between companies presenting at the conference and attending institutions are expected to mature into deals.
  • The second day of the event was devoted to business networking between Israeli technology companies participating in the conference, and hospital directors, medical distributors, and buyers from across the region.
  • Leading Israeli medical technology companies presented at the event: G-Medical, RenalSense , IGIN Smart, Appscent, Synergy 3d-Med, ALTA Medical , NeoPharm Israel , and Tuttenauer .

Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer

Retrieved on: 
Monday, January 10, 2022
SEC, LNP, Compte rendu, Hepatocellular carcinoma, Ipsen, Disease, Growth, Anchiano, Drexel University, Cell death, Bennett S. LeBow College of Business, Risk, Business administration, OEC, RNA transfection, Patient, Investment, ARIAD Pharmaceuticals, Research, Gene expression, Yan, Sanofi, Tel Aviv University, Bachelor, Oncology, Regenerative medicine, List of Israeli companies quoted on the Nasdaq, Master of Business Administration, Time, Meir Hospital, Therapy, Senior, Advanced Management Program, Harvard Business School, Private Securities Litigation Reform Act, OMEGA, Nasdaq, Technology, GlaxoSmithKline, Vaccine, COVID-19, Flagship Pioneering, Bristol Myers Squibb, Medicine, Yan Moore, Business, Biotechnology, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, today announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
  • Dr. Moore has extensive management, research, translational drug development and medical affairs experience across various pharmaceutical and biotechnology companies.
  • "The OMEGA Epigenomic Programming platform has the potential to provide meaningful, disease modifying treatments to patients and families in need," said Dr. Moore.
  • As a clinician, Dr. Moore spent time at Sapir Medical Center, Meir Hospital and Edith Wolfson Medical Center.